Logo

thalassemia

Vertex Appeals Ruling That Fertility Support for Casgevy Patients Would Violate Kickback Laws

A federal district court had ruled in favor of HHS, restricting Vertex's ability to provide fertility preservation services to Medicaid patients.

Court Sides With HHS, Blocking Vertex Program to Cover Fertility Services for Patients on Casgevy

HHS had argued that Vertex's plan to cover fertility services for some patients that took its gene therapy would violate anti-kickback and inducement laws.

HHS Calls Vertex's Case for Fertility Program a 'Distraction,' Urges Court to Rule in Its Favor

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run afoul of anti-kickback laws.

Vertex Gains Rights to Orna Therapeutics' Drug Delivery Tech in $1.07B Deal

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

Editas Medicine Lays off 65 Percent of Workforce; Drops Sickle Cell, TDT Candidate Reni-Cel

Editas, which was unable to identify a development or licensing partner for reni-cel, is focusing its resources on its in vivo pipeline.